Capabilities by Industry

Greenhill and its Managing Directors have extensive experience in a wide range of industries, including substantially all major industry areas with meaningful corporate transaction activity.

Recent Transactions

27-Jun-16
$156 million
United States flag
Target: 

ReachLocal

United States flag
Acquiror: 
Gannett

Served as independent financial advisor to the Board of Directors of Gannett in connection with its acquisition of ReachLocal

21-Jun-16
$586 million
Israel flag
Target: 

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

20-Jun-16
$NA
Israel flag
Target: 

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

17-Jun-16
$310 million
United Kingdom flag
Target: 

Dobbies Garden Centres

United Kingdom flag
Acquiror: 
Investor group led by Midlothian Capital Partners and Hattington Capital

Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital

16-Jun-16
$40 million
Israel flag
Target: 

US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

Pages

show all